Structure-based identification of potent fibroblast growth factor receptor 4 (FGFR4) inhibitors as potential therapeutics for hepatocellular carcinoma
PeerJ · 2025
DOI: 10.7717/peerj.19183 ↗Kurz gefasst
Fachartikel in der Zeitschrift PeerJ, 2025. Verfasst von Lin Fan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Zhongnan Hospital of Wuhan University, Institute of Hepatobiliary Diseases of Wuhan University, Transplant Center of Wuhan University, National Quali…. Hauptthemen laut MEDLINE: Receptor, Fibroblast Growth Factor, Type 4, Carcinoma, Hepatocellular, Liver Neoplasms, Antineoplastic Agents. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Research Supporting project by the National Natural Science Foundation of China.
Abstract (Originalsprache)
Fibroblast growth factor receptor 4 (FGFR4), a member of the fibroblast growth factor receptor family, plays a crucial role in cell growth, differentiation, and tissue repair. Increased FGFR4 expression has been detected in various cancers, including lung, liver, kidney and pancreatic cancer, making it a potential drug target. In this study, we conducted a structure-based virtual screening campaign to identify potential FGFR4 inhibitors. The retained compounds were further filtered based on pan assay interference compounds (PAINS) and absorption, distribution, metabolism, excretion, and toxicity (ADME/T) properties, leading to the identification of two promising candidates: MFCD00832235 and MFCD00204244. Quantum mechanical (QM) calculations revealed a large Highest Occupied Molecular Orbital (HOMO) and the Lowest Unoccupied Molecular Orbital (LUMO) (HUMO-LUMO) gaps for both compounds, indicating high dynamic stability and low chemical reactivity. Moreover, the stability of MFCD00832235 and MFCD00204244 at the adenosine triphosphate (ATP)-binding site of FGFR4 was confirmed through molecular dynamics (MD) simulations. The molecular mechanics Poisson-Boltzmann surface area (MM/PBSA) approach predicted favorable binding free energy values for both compounds with the target protein. In vitro assay revealed that MFCD00832235 and MFCD00204244 inhibited the growth of HepG2 cells with IC 50 values of 47.42 ± 12.93 µM and 77.83 ± 19.17 µM, respectively. Overall, this study suggested that MFCD00832235 and MFCD00204244 were potential FGFR4 inhibitors and may serve as start points for developing novel modulators of FGFR4 for cancer treatment, particularly hepatocellular carcinoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Zhongnan Hospital of Wuhan University, Institute of Hepatobiliary Diseases of Wuhan University, Transplant Center of Wuhan University, National Quality Control Center for Donated Organ Procurement, Hubei Key Laboratory…
- The 3rd Xiangya Hospital of Central South University, NHC Key Laboratory of Translational Research on Transplantation Medicine, Changsha, China.
Förderung
- The Research Supporting project by the National Natural Science Foundation of China
Zitieren
APA
Fan, L., Xie, H., Wang, W., Peng, G., Fu, Z., & Ye, Q. (2025). Structure-based identification of potent fibroblast growth factor receptor 4 (FGFR4) inhibitors as potential therapeutics for hepatocellular carcinoma. PeerJ. https://doi.org/10.7717/peerj.19183
Vancouver
Fan L, Xie H, Wang W, Peng G, Fu Z, Ye Q. Structure-based identification of potent fibroblast growth factor receptor 4 (FGFR4) inhibitors as potential therapeutics for hepatocellular carcinoma. PeerJ. 2025. doi:10.7717/peerj.19183
BibTeX
@article{Fan2025,
author = {Fan, Lin and Xie, Hui and Wang, Weiyu and Peng, Guizhu and Fu, Zhen and Ye, Qifa},
title = {Structure-based identification of potent fibroblast growth factor receptor 4 (FGFR4) inhibitors as potential therapeutics for hepatocellular carcinoma},
journal = {PeerJ},
year = {2025},
doi = {10.7717/peerj.19183}
}
EUVIMED